The deal will provide Harrow’s entire formulary compounded ophthalmic products to iOR Partners’ expanding office-based surgery locations across the United States.
Harrow and iOR Partners today jointly announced the expansion of their national product supply agreement to provide Harrow’s entire formulary compounded ophthalmic products to iOR Partners’ expanding office-based surgery locations across the United States.
In a news release, Mark L. Baum, chairman and CEO of Harrow, the company is pleased to be partnering with iOR Partners as they mobilize an increasing number of cataract surgeons to perform surgery in an office-based environment, offering more personalized care in a patient-friendly setting.
“iOR Partners assists practices nationwide to make office-based ophthalmic surgery a reality,” he said in a statement. Our mission has always focused on making medications accessible and affordable, and working with iOR Partners, the national leader in this fast-growing area of ophthalmic surgery, represents an important and growing channel for Harrow to meet our mission.”
“Harrow, through its ImprimisRx division, is the gold standard in supplying innovative compounded ophthalmic formulations that meet the highest federal manufacturing standards. Their commitment to quality, exceptional customer service, and the breadth of their portfolio are why we chose them as our partner,” Tony Burns, founder and principal of iOR Partners, said in the release. “These qualities support our confidence that we are delivering on our promise of personalized care that’s safe and comfortable for patients.”
“One excellent example of a product we find compelling is the MKO Melt, which has allowed us to substantially reduce the use of opioids and needles during office-based surgical procedures,” Burns added in the statement. “As we continue to grow and assist cataract surgeons with their vision of providing office‑based cataract surgery, we look forward to collaborating to further expand our services.”